Sustained-Release Naltrexone for Opioid Dependence

Ross Stanton, MD, JD, MPH
Joshua Lujan, DO
Christina Valerio, MD, MPH

American Family Physician. 2026;113(3):217A-217B.

Author disclosure: No relevant financial relationships.

ROSS STANTON, MD, JD, MPH; JOSHUA LUJAN, DO; and CHRISTINA VALERIO, MD, MPH, Scott Air Force Base, Illinois

Address correspondence to Christina Valerio, MD, MPH, at christina.r.valerio.mil@health.mil.

Author disclosure: No relevant financial relationships.

  1. 1.Degenhardt L, Webb P, Colledge-Frisby S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and enviornmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e659-e672.
  2. 2.World Health Organization, Department for HIV, Tuberculosis, Hepatitis and Sexually Transmitted Infections. People who inject drugs. Accessed February 13, 2026. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/populations/people-who-inject-drugs
  3. 3.Kornør H, Lobmaier PPK, Kunøe N. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2025(5):CD006140.

Copyright ©2026 MD Aware, LLC (theNNT.com). Used with permission.

This series is coordinated by Christopher W. Bunt, MD, AFP assistant medical editor, and the NNT Group.

A collection of Medicine by the Numbers published in AFP is available at https:// www.aafp.org/afp/mbtn.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.